Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047117 | 0.86 | IP6K1 (0.36) | KMT2A | |
| SCHEMBL22938869 | 0.86 | IP6K1 (0.36) | KMT2A | |
| SCHEMBL22938716 | 0.79 | ABL1 (0.46) | — | |
| SCHEMBL22938366 | 0.78 | TTR (0.38) | KMT2A | |
| SCHEMBL22938733 | 0.72 | TTR (0.40) | KMT2A | |
| SCHEMBL22938425 | 0.72 | TTR (0.40) | KMT2A | |
| SCHEMBL22939114 | 0.71 | TTR (0.39) | KMT2A | |
| SCHEMBL22939113 | 0.71 | TTR (0.39) | KMT2A | |
| SCHEMBL22938871 | 0.71 | TTR (0.34) | KMT2A | |
| SCHEMBL22938706 | 0.69 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | disclosed |
| WO-2021018194-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ABL1, ABL2, BCR | KMT2A 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.